These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 28888268)

  • 1. A randomized, multicenter, open-label, blinded end point trial comparing the effects of spironolactone to chlorthalidone on left ventricular mass in patients with early-stage chronic kidney disease: Rationale and design of the SPIRO-CKD trial.
    Hayer MK; Edwards NC; Slinn G; Moody WE; Steeds RP; Ferro CJ; Price AM; Andujar C; Dutton M; Webster R; Webb DJ; Semple S; MacIntyre I; Melville V; Wilkinson IB; Hiemstra TF; Wheeler DC; Herrey A; Grant M; Mehta S; Ives N; Townend JN
    Am Heart J; 2017 Sep; 191():37-46. PubMed ID: 28888268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of Spironolactone and Chlorthalidone on Cardiovascular Structure and Function in Chronic Kidney Disease: A Randomized, Open-Label Trial.
    Edwards NC; Price AM; Mehta S; Hiemstra TF; Kaur A; Greasley PJ; Webb DJ; Dhaun N; MacIntyre IM; Farrah T; Melville V; Herrey AS; Slinn G; Wale R; Ives N; Wheeler DC; Wilkinson I; Steeds RP; Ferro CJ; Townend JN
    Clin J Am Soc Nephrol; 2021 Oct; 16(10):1491-1501. PubMed ID: 34462286
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: a randomized controlled trial.
    Edwards NC; Steeds RP; Stewart PM; Ferro CJ; Townend JN
    J Am Coll Cardiol; 2009 Aug; 54(6):505-12. PubMed ID: 19643310
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spironolactone to prevent cardiovascular events in early-stage chronic kidney disease (STOP-CKD): study protocol for a randomized controlled pilot trial.
    Ng KP; Jain P; Heer G; Redman V; Chagoury OL; Dowswell G; Greenfield S; Freemantle N; Townend JN; Gill PS; McManus RJ; Ferro CJ
    Trials; 2014 May; 15():158. PubMed ID: 24886272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rationale and design of the Mineralocorticoid Receptor Antagonists in End-Stage Renal Disease Study (MiREnDa).
    Hammer F; Krane V; Störk S; Röser C; Hofmann K; Pollak N; Allolio B; Wanner C
    Nephrol Dial Transplant; 2014 Feb; 29(2):400-5. PubMed ID: 24166468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized controlled trial of the effect of spironolactone on left ventricular mass in hemodialysis patients.
    Hammer F; Malzahn U; Donhauser J; Betz C; Schneider MP; Grupp C; Pollak N; Störk S; Wanner C; Krane V;
    Kidney Int; 2019 Apr; 95(4):983-991. PubMed ID: 30712923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Spironolactone and chlorthalidone in uncontrolled elderly hypertensive patients treated with calcium antagonists and angiotensin II receptor-blocker: effects on endothelial function, inflammation, and oxidative stress.
    Yamanari H; Nakamura K; Miura D; Yamanari S; Ohe T
    Clin Exp Hypertens; 2009 Oct; 31(7):585-94. PubMed ID: 19886856
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term effects of spironolactone in peritoneal dialysis patients.
    Ito Y; Mizuno M; Suzuki Y; Tamai H; Hiramatsu T; Ohashi H; Ito I; Kasuga H; Horie M; Maruyama S; Yuzawa Y; Matsubara T; Matsuo S;
    J Am Soc Nephrol; 2014 May; 25(5):1094-102. PubMed ID: 24335969
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of spironolactone and angiotensin-converting enzyme inhibitor on left ventricular hypertrophy in patients with essential hypertension.
    Sato A; Suzuki Y; Saruta T
    Hypertens Res; 1999 Mar; 22(1):17-22. PubMed ID: 10221346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Efficacy and safety of long-term application of spironolactone in patients with moderate and severe chronic heart failure receiving optimal therapy].
    Skvortsov AA; Mareev VY; Chelmakina SM; Baklanova NA; Belenkov IuN
    Kardiologiia; 2007; 47(10):12-23. PubMed ID: 18260939
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized study of the beneficial effects of aldosterone antagonism on LV function, structure, and fibrosis markers in metabolic syndrome.
    Kosmala W; Przewlocka-Kosmala M; Szczepanik-Osadnik H; Mysiak A; O'Moore-Sullivan T; Marwick TH
    JACC Cardiovasc Imaging; 2011 Dec; 4(12):1239-49. PubMed ID: 22172779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study.
    Pitt B; Reichek N; Willenbrock R; Zannad F; Phillips RA; Roniker B; Kleiman J; Krause S; Burns D; Williams GH
    Circulation; 2003 Oct; 108(15):1831-8. PubMed ID: 14517164
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rationale and design of a multicentre, randomized, placebo-controlled trial of mirabegron, a Beta3-adrenergic receptor agonist on left ventricular mass and diastolic function in patients with structural heart disease Beta3-left ventricular hypertrophy (Beta3-LVH).
    Pouleur AC; Anker S; Brito D; Brosteanu O; Hasenclever D; Casadei B; Edelmann F; Filippatos G; Gruson D; Ikonomidis I; Lhommel R; Mahmod M; Neubauer S; Persu A; Gerber BL; Piechnik S; Pieske B; Pieske-Kraigher E; Pinto F; Ponikowski P; Senni M; Trochu JN; Van Overstraeten N; Wachter R; Balligand JL
    ESC Heart Fail; 2018 Oct; 5(5):830-841. PubMed ID: 29932311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aldosterone receptor antagonism induces reverse remodeling when added to angiotensin receptor blockade in chronic heart failure.
    Chan AK; Sanderson JE; Wang T; Lam W; Yip G; Wang M; Lam YY; Zhang Y; Yeung L; Wu EB; Chan WW; Wong JT; So N; Yu CM
    J Am Coll Cardiol; 2007 Aug; 50(7):591-6. PubMed ID: 17692742
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial-a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25 mg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone: study protocol for a randomized controlled trial.
    Hill NR; Lasserson D; Thompson B; Perera-Salazar R; Wolstenholme J; Bower P; Blakeman T; Fitzmaurice D; Little P; Feder G; Qureshi N; Taal M; Townend J; Ferro C; McManus R; Hobbs FR
    Trials; 2014 May; 15():160. PubMed ID: 24886488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-Term Effects of Low-Dose Spironolactone on Chronic Dialysis Patients: A Randomized Placebo-Controlled Study.
    Lin C; Zhang Q; Zhang H; Lin A
    J Clin Hypertens (Greenwich); 2016 Feb; 18(2):121-8. PubMed ID: 26224543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stabilization of Early Duchenne Cardiomyopathy With Aldosterone Inhibition: Results of the Multicenter AIDMD Trial.
    Raman SV; Hor KN; Mazur W; Cardona A; He X; Halnon N; Markham L; Soslow JH; Puchalski MD; Auerbach SR; Truong U; Smart S; McCarthy B; Saeed IM; Statland JM; Kissel JT; Cripe LH
    J Am Heart Assoc; 2019 Oct; 8(19):e013501. PubMed ID: 31549577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Results and lessons from the Spironolactone To Prevent Cardiovascular Events in Early Stage Chronic Kidney Disease (STOP-CKD) randomised controlled trial.
    Ng KP; Jain P; Gill PS; Heer G; Townend JN; Freemantle N; Greenfield S; McManus RJ; Ferro CJ
    BMJ Open; 2016 Feb; 6(2):e010519. PubMed ID: 26916697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence, predictors, and outcomes related to hypo- and hyperkalemia in patients with severe heart failure treated with a mineralocorticoid receptor antagonist.
    Vardeny O; Claggett B; Anand I; Rossignol P; Desai AS; Zannad F; Pitt B; Solomon SD;
    Circ Heart Fail; 2014 Jul; 7(4):573-9. PubMed ID: 24812304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted LOWering of Central Blood Pressure in patients with hypertension: Baseline recruitment, rationale and design of a randomized controlled trial (The LOW CBP study).
    Sharman JE; Stanton T; Reid CM; Keech A; Roberts-Thomson P; Stewart S; Greenough R; Stowasser M; Abhayaratna WP
    Contemp Clin Trials; 2017 Nov; 62():37-42. PubMed ID: 28822828
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.